Floatz logo

Osimertinib

Circulating Tumor Cell

Second Affiliated Hospital of Nanchang UniversitySmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Circulating Tumor Cell cohort.

Asset / SponsorPhaseRating
Piritramide
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4BB
NEPENTHE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4BB
Capecitabine
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3B
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3B
TRASTUZUMAB
AC Camargo Cancer Center
Phase 2CCC

View all 12 →

Same molecule, other indications

Osimertinib is also rated in:

EGFR Exon 19 DeletionDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →